[(1R)-1-phenylethyl] (2R,4S)-2-[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy]-2-oxo-1,3,2lambda5-thiazaphospholidine-4-carboxylate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: [(1R)-1-phenylethyl] (2R,4S)-2-[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy]-2-oxo-1,3,2lambda5-thiazaphospholidine-4-carboxylate
• 英文别名: [(1R)-1-phenylethyl] (2R,4S)-2-[[(2R,3R,4R,5R)-5-(2-amino-6-methoxypurin-9-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy]-2-oxo-1,3,2λ5-thiazaphospholidine-4-carboxylate
• 化学式: C₂₃H₂₉N₆O₈PS
• 分子量: 580.6
• InChiKey: UBSKQYRONNPCKU-WAFQCWJTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  39
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  219
• 氢给体数：
  4
• 氢受体数：
  14

文献信息

• [EN] THIOPHOSPHATE NUCLEOSIDES FOR THE TREATMENT OF HCV<br/>[FR] NUCLÉOSIDES DE THIOPHOSPHATE POUR LE TRAITEMENT DU VHC
  申请人：IDENIX PHARMACEUTICALS INC

  公开号：WO2014137930A1

  公开（公告）日：2014-09-12

  Provided herein are compounds, compositions, and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, the compounds are according to Formula 2001; where PD, Base, RA and RB are as provided herein. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.